V entricular arrhythmias due to coronary artery disease are a leading cause of death in the United States. 1 Patients with ventricular fibrillation (VF) or ventricular tachycardia (VT) without a reversible cause are at high risk of sudden death. 2, 3 Trials of secondary prevention of sudden death such as the antiarrhythmics versus implantable defibrillator (AVID) trial have shown that implantable cardioverter defibrillators (ICD) reduce the risk of death. [4] [5] [6] Conversely, it is thought that VT or VF in the setting of a reversible cause such as ischemia or electrolyte abnormalities has a low risk of recurrent arrhythmias and such patients were excluded from the ICD trials. Current guidelines do not recommend ICD implantation in survivors of cardiac arrest due to a potentially reversible cause including the acute phase (24 to 48 hours) of myocardial infarction (MI). 7, 8 VF in particular is thought to occur as a consequence of ischemia, and thus should be amenable to treatment of ischemia, as opposed to monomorphic VT, which is more common late after myocardial infarction due to reentry around scar. Nonetheless other studies have shown the converse; namely that patients with a potentially reversible cause have a higher mortality in comparison to patients with an established and fixed etiology. 9 The role of ICD implantation in this population has not been systematically examined in the era of widespread application of rapid coronary revascularization and ICD implantation. 10, 11 The aim of this study is to investigate the impact of ICD implantation on long-term outcomes of survivors of VF out-ofhospital cardiac arrest (OHCA) due to acute MI or myocardial ischemia.
Methods Study Population
The study included all patients who received defibrillation by emergency medical personnel for OHCA due to VF with return of spontaneous circulation and survived to discharge in Olmsted County, MN between November 1990 and March 2011. The study was approved by the Institutional Review Boards of Mayo Clinic and Olmsted Medical Center, Rochester, MN. All patients provided consent for the use of medical records for research purposes. Patient demographic data was collected prospectively, while treatment and outcomes were determined retrospectively.
All patients received advanced cardiac life support and early defibrillation by emergency medical personnel. Mayo Clinic, Rochester receives all patients resuscitated for OHCA in Olmsted County. Data regarding baseline characteristics and inpatient management were obtained from Mayo Clinic medical records. The etiology of VF was divided into (1) acute MI, (2) acute myocardial ischemia, and (3) nonischemic etiology. In all cases the rhythm was confirmed by review by an experienced physician who established the Olmsted County resuscitation program (RDW). Acute MI was diagnosed based on elevation of cardiac enzymes (CK-MB or troponin T) and electrocardiographic changes (new ST segment-T wave changes, new left bundle branch block or new pathologic q waves) or angiographic evidence of plaque rupture or thrombosis as per the Universal definition of Myocardial Infarction. 12 Elevation of cardiac enzymes less than 2 times the upper limit of normal was not considered to be evidence of MI since such elevation can also be seen in the setting of cardiac resuscitation without an acute coronary event. 8 Patients without evidence for acute MI who had symptoms of myocardial ischemia prior to the arrest and angiographic evidence of significant coronary artery disease (CAD) (>70% stenosis of 1 or more major epicardial coronary arteries) were considered to have acute myocardial ischemia without infarct. One hundred and nine patients (96%) underwent echocardiographic assessment of left ventricular ejection fraction during the hospitalization and repeat assessment was performed in 60 (52%) at a median of 137 (interquartile range 49 to 445) days following discharge. The ejection fraction during index hospitalization was used for analysis. The cerebral performance category (CPC) score was determined prospectively at the time of hospital discharge. 13, 14 CPC score of ≥3 was defined as poor neurologic outcome at discharge. The outcomes of interest were all-cause mortality, cardiac mortality, and appropriate ICD therapy. Variables related to ICD implantation and subsequent device therapies were obtained from the Mayo Clinic ICD database. All stored device therapy episodes were examined by an electrophysiologist or a specially trained electrophysiology device nurse prospectively to classify them as appropriate or inappropriate. Appropriate ICD therapy was defined as termination of a ventricular arrhythmia with antitachycardia pacing or shock therapy. The ventricular rate prior to the first ICD therapy following implantation was noted when available. All patients were primarily followed in the Mayo device clinic for ICD management and ICD follow-up was considered to have terminated for the purposes of this study if they transferred care to another institution. Data on mortality and cause of death was obtained from the Minnesota Death Index. Cardiac mortality was defined as death primarily due to coronary artery disease, heart failure, cardiac arrhythmias, or sudden death.
Statistical Methods
Categorical variables are summarized as N (%) and compared using the chi-square test. Continuous variables are summarized using mean (SD) or median (interquartile range, IQR) as appropriate and compared using t test or rank sum test. A temporal trend for ICD implantation was analyzed by forming 6 groups of 19 subjects according to date of arrest and plotting the percent of ICD device use versus the mean date of arrest. For mortality analyses, date of arrest was used as time zero. A timedependent variable was used to model the effect of ICD implantation (in both unadjusted and multivariable models), since implantation may have occurred up to 8 weeks post arrest. For Kaplan-Meier survival plots, a landmark approach was used, with landmark time at 8 weeks, so that any events prior to that time were excluded. For analysis of ICD events in those implanted with the device, time zero was the date of implantation. Cox proportional hazards models were used to estimate both unadjusted and adjusted hazard ratios (95% confidence interval). Covariates for adjustment were chosen from among risk factors that were significant (P<0.05) in the age-adjusted analysis. To avoid estimation problems due to too many variables in the model for cardiac death, we collapsed covariates into a single measure using principal components analysis. After principal components were estimated, the first principal component was used as the covariate for risk adjustment. Principal component analysis is also presented for all-cause mortality. The increased risk of subsequent ICD therapy after 8 months due to early (within first 8 months) ICD therapy was estimated using Poisson regression on the number of events and with the log of follow-up time included as an offset variable. A 2-tailed P<0.05 was considered statistically significant. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).
Results

Outcomes of VF Out of Hospital Cardiac Arrest
Of the 333 patients treated by emergency medical personnel for VF OHCA, 68 (20%), 19 (6%) and 90 (27%) patients died pre-hospital, in the emergency room and in the hospital, respectively. One hundred and fifty-six (47%) patients survived to hospital discharge, of whom 114 (73%) were determined to have acute myocardial infarction (AMI) or ischemia as the etiology of the arrest. The etiology of the arrest in the other 42 (27%) patients included dilated cardiomyopathy (n=12), idiopathic VF (8), channelopathy (3), Torsades de pointes (3), myocarditis (2) , flail mitral leaflet with severe mitral regurgitation (2), drug induced coronary vasospasm (2), amyloid heart disease (1), hypokalemia (1), and was unknown in 8 patients. Our investigation focuses on the outcomes of 114 survivors of VF arrest due to AMI or ischemia.
Characteristics of Patients With VF Arrest due to Acute Myocardial Infarction or Ischemia
The mean age of survivors of VF OHCA due to AMI or ischemia was 63.5 (11.5) years and 93 (82%) were males. Ninety-one (80%) were diagnosed with AMI (STEMI in 48 and NSTEMI in 43) at the time of the OHCA. Myocardial ischemia related to significant CAD was the likely etiology of VF arrest in 23 (20%). Coronary angiography was performed in 105 (92%) patients during the same admission. Angiography was not performed in the remaining due to known CAD with anatomy unsuitable for revascularization (n=4), significant hypoxic encephalopathy (n=3), and patient's refusal to undergo angiography (n=2). Coronary revascularization was successfully performed in 67 (59%) patients (percutaneous coronary intervention in 42 and coronary artery bypass surgery in 25) prior to discharge.
An ICD was implanted in 45 (39%) patients within 8 weeks of the index event. The median (IQR) time interval to ICD implantation was 9 (7, 14) days. One patient underwent ICD implantation 1.3 years after the OHCA due to a persistently low EF and was included in the group with no ICD for the purposes of this analysis. The characteristics of patients with and without ICD implantation are presented in Table 1 . The CPC score was 1 in 105 (92.1%), 2 in 2 (1.7%), 3 in 6 (5.3%), and 4 in 1 (0.9%) patient. Amiodarone was the most common anti-arrhythmic drug prescribed at discharge and was more likely to be prescribed to patients without an ICD (7 versus 21%, P=0.04).
Risk Factors for Mortality
Fifty-one (45%) patients died over a median follow-up of 9.9 (4.4 to 14.6) years. Survival at 1, 3, and 5 years was 94%, 86%, and 74%, respectively. The majority of patients died of non-cardiovascular illnesses (50%) including malignancy (n=13), anoxic brain injury secondary to the cardiac arrest (n=6), chronic obstructive lung disease (n=3), sepsis (n=2), Alzheimer's dementia (n=1), and presumptive diagnosis of dehydration in a 97-year-old (n=1). Cardiovascular mortality occurred in 18/114 (16%) patients. The etiology of cardiovascular death included heart failure (n=9), sudden death in patients without ICD (n=5), acute myocardial infarction (n=3), and stroke secondary to atrial fibrillation (n=1). The cause of death could not be adjudicated in 7 patients.
When adjusted for age, the risk factors for all-cause mortality were: (1) (Figure 2A ). In the multivariable model, age, peripheral vascular disease, creatinine at discharge, CPC score ≥3, and heart failure independently predicted greater all-cause mortality ( Figure 2B . ICD implantation was 
Appropriate ICD Therapy in Survivors of VF Arrest
One or more appropriate therapies were delivered by the ICD in 19 (42%) of the 45 ICD recipients over a median follow-up of 4.6 (2.7 to 12.3) years. Figure 3 shows the Kaplan-Meier analysis of time to first appropriate ICD therapy stratified by EF. The cumulative incidence of first ICD therapy at 1, 2, and 4 years was 24%, 29%, and 38%, respectively. Two patients received appropriate therapy within 40 days of the OHCA. The risk for first ICD therapy was highest in the first year after implantation. Of the patients who received an appropriate therapy, 53% did so in the first year. In patients with EF >35%, 4 of 22 patients received 1 or more ICD therapies, the risk being the highest in the first 8 months following which no first-time ICD discharges were seen. In contrast, patients with EF ≤35% continued to experience first appropriate ICD therapy throughout the period of follow-up. An appropriate ICD therapy in the first 8 months increased the risk of subsequent therapies, (risk ratio 8.8, 95% CI 6.2 to 12.5). The rate of appropriate ICD therapy in the subgroup with acute MI was similar to the overall cohort: 29 and 33% at 1 and 2 years, respectively.
In univariate analysis, appropriate ICD discharge was associated with advanced age (66.4 [8.6] 
Recurrent VT/VF or Sudden Death in Patients Without ICD Implantation
Of the 63 patients who did not undergo ICD implantation, 5 experienced sudden death and 1 had syncope with documented ventricular arrhythmia a median of 530 (interquartile range 272 to 1828) days after the index event. This included 2 patients who declined ICD, 1 patient with hypoxic encephalopathy, and 2 patients with and without revascularization with EF >35%. Patients who experienced recurrent arrhythmia or sudden death were significantly older (75 [14] versus 63 [11] %, P=0.02). All 6 patients had the index OHCA event in the setting of an AMI but only 2 were revascularized. The median EF of the 6 patients was 27 (range 20 to 47.5)%. Only 1 patient who experienced subsequent sudden death was revascularized and had an ejection fraction >35% at the time of the index OHCA.
Discussion
We present the long-term outcomes following ICD implantation for out-of-hospital cardiac arrest due to VF in the setting of acute myocardial infarction or ischemia in a populationbased cohort. The main findings of the study are: (1) ICD implantation may be associated with reduced cardiac mortality after adjusting for other risk factors, (2) risk factors for allcause mortality include advanced age, higher serum creatinine levels, peripheral vascular disease, cerebral performance category, and heart failure, (3) 40% of ICD recipients received 1 or more appropriate therapies, (4) patients with EF ≤35% at discharge continued to be at long-term risk for recurrent ventricular arrhythmias and patients with EF >35% are at increased risk for recurrent ventricular arrhythmias in the first 8 months following OHCA, and (5) ejection fraction and revascularization were not predictive of ICD therapy after adjusting for confounders.
In VF OHCA due to a potentially reversible cause, namely acute myocardial infarct or ischemia, ICD implantation was not statistically significantly associated with reduced all-cause mortality after adjusting for potential confounders, but showed a trend towards significance. ICD implantation was not a significant predictor of cardiac mortality in the univariate analysis, likely due to potential confounders such as lower ejection fraction in ICD recipients. The small number of events for cardiac mortality did not allow adjusting for individual confounders, but ICD implantation was a significant predictor of cardiac mortality in a principal component analysis. These results should be considered hypothesis generating only and confirmed in larger cohorts of patients. Since patients with poor neurological recovery following OHCA are often not good candidates for ICD implantation, the mortality risk analysis was repeated in the cohort of "neurologically intact survivors of OHCA." ICD implantation was not statistically significantly associated with all-cause mortality, although a trend towards reduced mortality (P=0.07) was observed in those with CPC <3. When the subgroup with acute MI alone was considered, ICD implantation again was not significantly predictive of all-cause mortality. The mortality rate of survivors of OHCA in our study is comparable to that reported by Borleffs et al in the Leiden outof-hospital cardiac arrest study. 15 The predictors of death in the current study included higher age, poor renal function, poor neurological recovery following OHCA, peripheral artery disease, and heart failure. The majority of deaths were, however, due to non-cardiac illness or heart failure, with arrhythmic death being uncommon even among patients without an ICD. Over a median follow-up of 4.6 years, 40% of ICD recipients received at least 1 appropriate therapy. This was also true of the subgroup with acute MI as the etiology of VF arrest. The high risk despite a reversible cause as the presumed trigger likely reflects the substantial residual substrate abnormalities in many patients. The rate of ICD therapy in this study (35% at 3 years) is lower than that observed in trials of secondary prevention of sudden death due to a non-reversible cause such as AVID (69% at 3 years) and higher than that noted in primary prevention trials (21% at 3.8y in SCDHeFT). 4, 16 Our findings are, however, comparable to the rate of appropriate ICD therapy noted in the Leiden out-of-hospital cardiac arrest study, which included patients with an "irreversible cause." 15 The higher rate of ICD therapy noted in the AVID trial could be explained by the limited capability in the trial to differentiate appropriate from inappropriate therapy. These results should also be interpreted in light of the fact that differences in ICD programming significantly influence ICD therapy rate. Patients with EF ≤35% at the time of discharge were at higher risk of recurrent ventricular arrhythmia. This suggests that the magnitude of myocardial injury at the time of the index event and potentially LV function prior to OHCA modulates the risk of subsequent VT/VF. This is consistent with observations from randomized controlled trials of secondary prevention in which patients with EF <35% benefit the most from ICD implantation. A retrospective analysis of the AVID trial and a meta-analysis of 3 secondary prevention trials noted that while ICD improved survival in patients with EF <35%, survival of those with EF ≥35% was similar to that of patients treated with antiarrhythmic drug. 17, 18 Despite the overall lower risk of ICD therapy, patients with EF >35% were at risk of ICD therapy in the first 8 months after OHCA. Absence of arrhythmia recurrence in the first 8 months predicted continued arrhythmia-free survival in the long term. Heart failure and myocardial remodeling soon after an MI may explain increased risk for early recurrence of arrhythmia. However, the continued long-term risk for recurrent VT/VF in patients with early recurrence could suggest the persistence of an underlying arrhythmic substrate in these patients. Epstein et al reported the feasibility and efficacy of use of a wearable cardiac defibrillator in high risk patients following AMI. 19 Our results suggest that temporary defibrillator support such as the wearable cardiac defibrillator may be reasonable in OHCA survivors with EF >35%, with no further escalation to ICD implantation in the absence of a relatively early recurrence of ventricular arrhythmia.
Half of the ICD recipients who had recurrent arrhythmia did so in the first year and early recurrence increased the risk for subsequent arrhythmia by 8-fold. Prior studies have shown a similar high risk of death from arrhythmias in the first 6 to 12 months after an AMI in patients without OHCA. [20] [21] [22] However, the randomized controlled DINAMIT and IRIS trials did not show improved overall survival with ICD implantation following recent MI despite a reduction in arrhythmic death. 23, 24 Of note, patients with a primary VF arrest were excluded from randomization in these trials. The findings of the current study parallel these findings and suggest that the reduced cardiac mortality due to early ICD implantation after VF OHCA may be offset by increased mortality due to noncardiac causes.
We could not identify a clinically relevant subgroup of patients completely free of ICD therapy. EF was not significantly associated with subsequent ICD therapy in the multivariable analysis, although effect of the small sample size cannot be ruled out. While patients who presented with coronary ischemia without infarction were more likely to receive an ICD compared with those who presented with AMI, the initial presentation did not significantly predict subsequent ICD therapies. Furthermore, while revascularization was protective of recurrent VT/VF in the univariate analysis, this was not the case after adjusting for age and EF. These findings underscore the difficulty in clinically identifying patients who are truly at low risk even in the presence of a so-called "reversible cause."
Limitations
The current study has the limitations of a retrospective nonrandomized, single-center study. The decision to implant an ICD was likely biased by multiple factors and only known confounders were adjusted for using multivariable analysis. There may be unknown confounders for which we could not adjust. Furthermore, the small sample size limited our ability to adjust for confounders. Our finding of significant association between ICD implantation and reduced cardiac mortality was based on adjusting for the first principal component of the risk factors, which is not the same as adjusting for the risk factors themselves and certainly involves some loss of information. The sample size also limited our power to detect small differences in the outcomes of interest as was noted with the impact of ICD implantation on all-cause mortality.
This highlights the need for a prospective large, multicenter, randomized study of the utility of ICD implantation in this population. Distinguishing myocardial ischemia as the primary etiology of VF from ischemia secondary to the arrest can be challenging. We restricted our analysis to patients who had documented symptoms of ischemia prior to the arrest and significant CAD. Further subgroup analysis of patients with acute MI only showed trends similar to the overall cohort, ie, no significant association between ICD implantation and survival. Therapy delivered by an ICD does not always equate to aborted sudden death and device programming can significantly affect the number of therapies delivered. The majority of ICD-treated VT/VF had rate >180 bpm and was highly likely to be clinically relevant. Moreover, the occurrence of appropriate therapies does indicate the continued presence of a substrate for recurrent ventricular arrhythmias in this population. The risk analysis in this study was based on events at the time of the index OHCA and subsequent outcomes could have been affected by dynamic changes in the disease process. Finally, the use of administrative data to ascertain cause of death could potentially lead to misclassification.
Conclusions
We report outcomes following VF OHCA in the setting of acute MI or acute ischemia in a population-based sample. Patients with VF OHCA in the setting of acute MI or myocardial ischemia remain at high risk of recurrent ventricular arrhythmias and ICD implantation may be associated with reduced risk of cardiac mortality and a statistically non-significant trend towards reduction in all-cause mortality. The role of ICD implantation in VF OHCA due to a "potentially reversible cause" warrants further investigation in a large prospective multicenter registry and a randomized controlled trial. In the absence of such data, patients with pre-discharge EF ≤35% could reasonably be considered for ICD implantation due to significant long-term risk of recurrent arrhythmias and ICD therapy. Our findings in general support the recommendations for appropriate use of ICD published by the American Heart Association. 25 Patients with EF >35% have a significant early risk, which then stabilizes; the use of a temporary defibrillator such as a wearable cardiac defibrillator and the role of ICD implantation should be further investigated.
